gene

REL

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about REL: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

148Connections

30Hypotheses

0Analyses

50Outgoing

48Incoming

11Experiments

0Debates

Summary

REL is a gene implicated in neurodegeneration research. Key relationships include: regulates, activates, expressed in. Associated with AD, ALI, AMI. Connected to 114 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	REL
Full Name	c-Rel Proto-Oncogene, NF-Kappa B Subunit
Chromosome	2p16.1
Function	REL (c-Rel) is a member of the NF-κB family that forms heterodimers with p50 and p52.
Primary Expression	hematopoietic cells, with lower expression in other tissues
Pathways	Akt, Apoptosis, Complement, Immune Response, Lipid Metabolism
UniProt ID	P41160
NCBI Gene ID	5966
Ensembl ID	ENSG00000162924
OMIM	164913
GeneCards	REL
Human Protein Atlas	REL
Associated Diseases	AD, Aging, ALI, Als, AMI, disease
Interactions	AND, APOPTOSIS, BCL2L1, CANCER, CYTOKINES, FOXO1
KG Connections	148 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: REL — AlphaFold P41160 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (6)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    REL["REL"] -->|"regulates"| Ms["Ms"]
    REL["REL"] -->|"regulates"| Inflammation["Inflammation"]
    REL["REL"] -->|"expressed in"| Lymphoma["Lymphoma"]
    REL["REL"] -->|"expressed in"| Als["Als"]
    REL["REL"] -->|"expressed in"| Ms_1["Ms"]
    REL["REL"] -->|"regulates"| Alzheimer["Alzheimer"]
    CERS2["CERS2"] -->|"regulates"| REL["REL"]
    CERS2_2["CERS2"] -->|"associated"| REL["REL"]
    CDKN2A["CDKN2A"] -->|"regulates"| REL["REL"]
    TP53["TP53"] -->|"regulates"| REL["REL"]
    style REL fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (100)

Target	Relation	Type	Str
INSC	regulates	gene	0.95
Als	activates	disease	0.85
Inflammation	regulates	disease	0.75
Cancer	activates	disease	0.75
Als	regulates	disease	0.75
Immune Response	regulates	pathway	0.70
Cancer	therapeutic_target	disease	0.65
Als	associated_with	disease	0.65
Breast Cancer	therapeutic_target	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Obesity	regulates	disease	0.65
Tumor	activates	disease	0.65
Cancer	regulates	disease	0.65
Cancer	contributes_to	disease	0.65
Carcinoma	activates	disease	0.65
Inflammation	activates	disease	0.65
Aging	associated_with	disease	0.65
Carcinoma	expressed_in	disease	0.65
Ms	expressed_in	disease	0.65
Alzheimer	protects_against	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Parkinson	associated_with	disease	0.65
Macular Degeneration	associated_with	disease	0.65
Traumatic Brain Injury	associated_with	disease	0.65
Stroke	protects_against	disease	0.65
Tumor	therapeutic_target	disease	0.65
Ms	causes	disease	0.65
Lymphoma	expressed_in	disease	0.65
Ms	regulates	disease	0.65
Alzheimer	regulates	disease	0.65
Als	expressed_in	disease	0.65
RELA	contributes_to	gene	0.60
RELB	therapeutic_target	gene	0.60
CD4	regulates	gene	0.60
RELA	therapeutic_target	gene	0.60
PRDM1	regulates	gene	0.60
CD8	regulates	gene	0.60
STAT3	associated_with	gene	0.60
IRF1	associated_with	gene	0.60
FOXO1	activates	gene	0.60
CERS2	regulates	gene	0.60
RELA	expressed_in	gene	0.60
RELB	expressed_in	gene	0.60
Apoptosis	activates	pathway	0.60
Complement	activates	pathway	0.60
CANCER	activates	gene	0.60
ALZHEIMER	regulates	gene	0.60
ALZHEIMER'S DISEASE	regulates	gene	0.60
Lipid Metabolism	causes	pathway	0.60
Sphingolipid	causes	pathway	0.60

Incoming (48)

Source	Relation	Type	Str
INFLAMMATION	regulates	gene	0.70
CYTOKINES	activates	gene	0.60
NF-ΚB	contributes_to	gene	0.60
INFLAMMATION	activates	gene	0.60
NF-ΚB	therapeutic_target	gene	0.60
INFLAMMATION	therapeutic_target	gene	0.60
PARKINSON	associated_with	gene	0.60
NF-ΚB	regulates	gene	0.60
ALZHEIMER	protects_against	gene	0.60
KRAS	activates	gene	0.60
CANCER	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
NF-ΚB	expressed_in	gene	0.60
APOPTOSIS	expressed_in	gene	0.60
NFKB	regulates	gene	0.60
ERBB2	regulates	gene	0.60
NF-KB	expressed_in	gene	0.60
NF-ΚB	interacts_with	gene	0.60
CERS2	regulates	gene	0.60
CERS2	associated_with	gene	0.60
CDKN2A	regulates	gene	0.60
TP53	regulates	gene	0.60
TET2	expressed_in	gene	0.60
MYD88	expressed_in	gene	0.60
KMT2D	expressed_in	gene	0.60
STAT3	regulates	gene	0.60
DDX3X	expressed_in	gene	0.60
RB1	regulates	gene	0.60
GNA13	expressed_in	gene	0.60
HDAC6	regulates	gene	0.60
MAP3K4	regulates	gene	0.60
CD4	regulates	gene	0.60
MTOR	regulates	gene	0.60
IL6	regulates	gene	0.60
TP53	activates	gene	0.60
MYC	activates	gene	0.60
SOD2	regulates	gene	0.60
AKT	regulates	gene	0.60
HIF1A	activates	gene	0.60
HRAS	regulates	gene	0.60
PPARG	activates	gene	0.60
GAPDH	regulates	gene	0.60
BCL2L1	activates	gene	0.60
TBK1	activates	gene	0.60
ALZHEIMER'S DISEASE	regulates	gene	0.60
IL-10	activates	gene	0.60
INSC	regulates	gene	0.60
RNA	inhibits	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
MAPT tau seeding and release across AD, FTD, and PD-spectrum	0.812	multi	Cross-disease neurodegeneration mechanis
Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Re	0.804	neurodegeneration	What are the mechanisms by which gut mic
Gamma entrainment induces activity-dependent BDNF release to	0.773	alzheimers	Gamma entrainment therapy to restore hip
Selective LXRβ agonists restore ABCA1/ABCG1 expression and A	0.763	neuroscience	APOE4-driven lipid metabolism dysregulat
Senescent Cell Mitochondrial DNA Release	0.742	neurodegeneration	Senolytic therapy for age-related neurod

APOE4-driven lysosome-to-ER cholesterol transport failure re	0.741	molecular-biology	Does APOE4's reduced lipid-binding direc
Calcium-Dependent S100B Release from Astrocyte End-Feet as a	0.725	-	What blood-brain barrier permeability ch
Gamma entrainment suppresses hippocampal ERK1/2 hyperactivit	0.711	alzheimers	Gamma entrainment therapy to restore hip
Spatiotemporal coupling between TRPML1-mediated lysosomal ca	0.705	neurodegeneration	What determines the specificity of calci
Time-Limited AQP4 Inhibition for Acute Cytotoxic Edema Follo	0.690	neurodegeneration	How can AQP4 be effectively targeted the
A downstream LRRK2-Rab10-JIP4 lysosomal stress loop promotes	0.680	neurodegeneration	Do pathogenic LRRK2 mutations amplify vo
Gamma entrainment corrects AD-related clock gene dysregulati	0.676	alzheimers	Gamma entrainment therapy to restore hip
FABP5/7 Inhibition (H2): Lipid Relay Interruption	0.670	neurodegeneration	Does restoring neuronal AMPK activity re
CDK5 Inhibition at Presynaptic Terminals Prevents Activity-D	0.640	neurodegeneration	Investigate prion-like spreading of tau
Targeting Synaptic Vesicle Release Machinery to Block Tau Ex	0.630	neuroscience	Trans-synaptic tau spreading and propaga
Subtle NMDAR Inhibition Attenuates Excitotoxicity-Driven Tau	0.620	neurodegeneration	Investigate prion-like spreading of tau
CSF ApoE- and clusterin-rich lipoprotein particles stabilize	0.606	neurodegeneration	Which specific CSF molecular components
microglial priming as a partially upstream causal node rathe	0.604	neurodegeneration	Microglial Priming as Upstream Causal No
Neuropeptide Y (NPY) Co-release from PV Interneurons Modulat	0.585	alzheimers	Closed-loop optogenetic targeting PV int
Pharmacological P2RY12 inhibition (ticagrelor/clopidogrel) a	0.583	neurodegeneration	How does P2RY12-mediated VSMC dysfunctio
Limited Calcium Release Without Sufficient Cathepsin Efflux	0.580	neurodegeneration	How does controlled lysosomal membrane p
H4: Age-Related Hsp70 Chaperone Decline Blocks Granule Rever	0.577	neurodegeneration	How do pathological stress granules tran
Hsp70-based therapy to prevent lysosomal membrane permeabili	0.570	neuroscience	Lysosomal dysfunction and cathepsin leak
TFEB Activation Clears Tau-Loaded Endolysosomal Compartments	0.560	neurodegeneration	Investigate prion-like spreading of tau
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microgli	0.555	neurodegeneration	TREM2 in Alzheimer's Disease: Mechanisms
H4: Polycomb Repression Relaxes at Neurodevelopment Genes	0.530	neurodegeneration	Investigate mechanisms of epigenetic rep
Microglial Reactivation Status Modifies Amyloid Clearance an	0.524	neurodegeneration	-
Severely Depleted mtDNA and Impaired OXPHOS Defines Senescen	0.520	neurodegeneration	How can senescent microglia be molecular
HDAC1/2 Complex Restoration Corrects Age-Related Histone Hyp	0.520	neurodegeneration	Investigate mechanisms of epigenetic rep
Lamin B1 Restoration Prevents Age-Related Nuclear Lamina Com	0.510	neurodegeneration	Investigate mechanisms of epigenetic rep

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (11)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
iPSC-derived astrocyte-neuron co-culture mitochondrial transfer in PD	exploratory	Parkinson's disease	0.900	0.00	iPSC-derived dopaminergic neur	proposed	N/A
REL transcription factor mediates VLC ceramide-driven inflammation	exploratory	inflammation	0.750	0.00	innate immune cells	proposed	N/A
Proposed experiment from debate on Senolytics targeting p16/p21+ senes	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Biomechanical Impact Profiles and Chronic Traumatic Encephalopathy Phe	clinical	Neurodegeneration	0.400	0.50	in_silico	proposed	$180,000
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk Cohorts	clinical	ALS	0.400	0.50	human	proposed	$6,550,000
cGAS-STING Pathway Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
Mixed Pathology Effects on Parkinson's Disease Progression and Treatme	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
NLRP3 Inflammasome Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Regulated Necrosis Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$6,550,000
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Traumatic Brain Injury and Alzheimer's Disease Relationship	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$3,000,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745]	Yu CH, Davidson S, Harapas CR, Hilton JB	Cell	2020	2
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiqui [PMID:30966861]	["Han X", "Sun S", "Sun Y", "Song Q", "Z	Autophagy	2020	1
Past, present and future perspectives on the science of aging. [PMID:41566049]	Fabrisia Ambrosio; Maxim N Artyomov; Ste	Nature aging	2026	0
Stimuli-responsive nanoplatforms for precision activation of the STING pathway i [PMID:41668757]	["Bi D", "Yang X", "Wang Y", "Yong J", "	Frontiers in immunology	2026	0
Decoding senescent drivers in Alzheimer's disease: From bench to bedside. [PMID:41344577]	["Zhou R", "Lin X", "Liao Z", "Lin J", "	Ageing research reviews	2026	0
Role of NEIL1 in genome maintenance. [PMID:40010204]	["McCullough A", "Minko I", "Luzadder M"	DNA repair	2025	0
Bionanoconjugates in Neurodegeneration: Peptide-Nanoparticle Alliances for Next- [PMID:41199078]	["Ranjitha V", "Kumar A", "Kaalappa P"]	Pharmaceutical research	2025	0
Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven imm [PMID:40203808]	["Lai P", "Liu L", "Bancaro N", "Troiani	Immunity	2025	0
Apheresis for senescence: Targeting the senescence-associated secretory phenotyp [PMID:40651559]	["Akgun Y"]	Ageing research reviews	2025	0
Methodological influences on circulating cell-free-mitochondrial and nuclear DNA [PMID:40080226]	["Daubermann C", "Herhaus B", "Neuberger	Molecular biology reports	2025	0
Innate immune sensing of Z-nucleic acids by ZBP1-RIPK1 axis drives neuroinflamma [PMID:40902587]	["Song Z", "Xie X", "Chen Y", "Zhang B",	Immunity	2025	0
Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746]	["Sanadgol N", "Abedi M", "Hashemzaei M"	Journal of nanobiotechnology	2025	0
Antileukemic potential of methylated indolequinone MAC681 through immunogenic ne [PMID:38704604]	["Orlikova-Boyer B", "Lorant A", "Gajula	Biomarker research	2024	0
Enhancing Radiofrequency Ablation for Hepatocellular Carcinoma: Nano-Epidrug Eff [PMID:39548919]	["Li X", "Liu Y", "Ke J", "Wang Z", "Han	Advanced materials (Deerfield	2024	0
The cGAS-STING pathway drives neuroinflammation and neurodegeneration via cellul [PMID:39490400]	Zhang Y, Zou M, Wu H, Zhu J, Jin T	Neurobiology of disease	2024	0
mtDNA release promotes cGAS-STING activation and accelerated aging of postmitoti [PMID:39039044]	["Li Y", "Cui J", "Liu L", "Hambright W"	Cell death & disease	2024	0
Senescent glia link mitochondrial dysfunction and lipid accumulation. [PMID:38839958]	["Byrns C", "Perlegos A", "Miller K", "J	Nature	2024	0
Apoptotic stress causes mtDNA release during senescence and drives the SASP. [PMID:37821702]	["Victorelli S", "Salmonowicz H", "Chapm	Nature	2023	0
Exposome and unhealthy aging: environmental drivers from air pollution to occupa [PMID:37688657]	Pandics T, Major D, Fazekas-Pongor V, Sz	GeroScience	2023	0
Inhibition of autophagy in microglia and macrophages exacerbates innate immune r [PMID:36652438]	Hegdekar N, Sarkar C, Bustos S, Ritzel R	Autophagy	2023	0

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning REL in their description or question text

REL

Understanding Entity Pages

Summary

Wiki Pages (6)

REL Gene

RELN Gene

RELA (p65) Protein

RELB Gene

RELB Protein

RELA (NF-κB p65)

Pathway Diagram

Outgoing (100)

Incoming (48)

Targeting Hypotheses (30)

Mentioning Analyses (0)

Experiments (11)

Related Papers (20)

Debates (0)

Related Research

APOE4-driven lysosome-to-ER cholesterol transport failure reduces ER-accessible

Calcium-Dependent S100B Release from Astrocyte End-Feet as an Early Signal of As

Gamma entrainment suppresses hippocampal ERK1/2 hyperactivity to decrease AD-rel

Spatiotemporal coupling between TRPML1-mediated lysosomal calcium release and ca

Time-Limited AQP4 Inhibition for Acute Cytotoxic Edema Followed by Therapeutic R

A downstream LRRK2-Rab10-JIP4 lysosomal stress loop promotes alpha-synuclein rel

Gamma entrainment corrects AD-related clock gene dysregulation to normalize hipp

FABP5/7 Inhibition (H2): Lipid Relay Interruption

CDK5 Inhibition at Presynaptic Terminals Prevents Activity-Dependent Tau Release

Targeting Synaptic Vesicle Release Machinery to Block Tau Exocytosis

Subtle NMDAR Inhibition Attenuates Excitotoxicity-Driven Tau Release from Hypers

CSF ApoE- and clusterin-rich lipoprotein particles stabilize disease-relevant al

microglial priming as a partially upstream causal node rather than a pure diseas

Neuropeptide Y (NPY) Co-release from PV Interneurons Modulates Aβ Toxicity

Pharmacological P2RY12 inhibition (ticagrelor/clopidogrel) as repurposing probe